Abstract
Spinal Cord Injury (SCI) is a complex process which leads to destruction of neuronal tissue and also vascular structure. After SCI many potentially toxic substances are activated and released into the injury site causing secondary degeneration.
Erythropoietin (EPO) is a possible therapeutic strategy to treat SCI. Over the last decade attention has been focused on the molecular mechanisms underlying its neuroprotective effects. A major concern expressed by clinicians is that besides its protective effects, EPO also demonstrates hematopoietic activity and increases the risk for thrombosis after the systemic administration of multiple doses of this glycoprotein. Recently, tissue protective functions of EPO have been separated from its hematopoietic actions leading to the development of EPO derivatives and mimetics. Neuroscientists are focusing on recombinant human EPO (rhEPO) and its non-erythropoietic derivatives, investigating their anti-apoptotic potential and anti-inflammatory function as well as their role in restoring vascular integrity. Carbamylated erythropoietin (CEPO) and asialo erythropoietin (AsialoEPO) are structural derivatives of EPO that have no effect on erythrocyte mass whereas they retain its neuroprotective effects. In this review article, we provide a short overview of the animal studies on rhEPO and its derivatives in experimental models of SCI.
Both the efficacy and the safety profile of EPO-structural and functional variants are still to be demonstrated in patients. Further clinical studies should reveal whether derivatives and variants of erythropoietin provide any benefits over the use of rhEPO in the treatment of spinal cord injury observed in the experimental studies.
Keywords: Erythropoietin, spinal cord injury, recombinant human erythropoietin, EPO-derivatives, carbamylated EPO, asialo EPO, safety profile, neuronal tissue, secondary degeneration, therapeutic strategy, neuroprotective effects, hematopoietic activity, thrombosis, glycoprotein, CEPO
Mini-Reviews in Medicinal Chemistry
Title: The Use of Erythropoietin and its Derivatives to Treat Spinal Cord Injury
Volume: 11 Issue: 9
Author(s): A. Mofidi, A. Bader and S. Pavlica
Affiliation:
Keywords: Erythropoietin, spinal cord injury, recombinant human erythropoietin, EPO-derivatives, carbamylated EPO, asialo EPO, safety profile, neuronal tissue, secondary degeneration, therapeutic strategy, neuroprotective effects, hematopoietic activity, thrombosis, glycoprotein, CEPO
Abstract: Spinal Cord Injury (SCI) is a complex process which leads to destruction of neuronal tissue and also vascular structure. After SCI many potentially toxic substances are activated and released into the injury site causing secondary degeneration.
Erythropoietin (EPO) is a possible therapeutic strategy to treat SCI. Over the last decade attention has been focused on the molecular mechanisms underlying its neuroprotective effects. A major concern expressed by clinicians is that besides its protective effects, EPO also demonstrates hematopoietic activity and increases the risk for thrombosis after the systemic administration of multiple doses of this glycoprotein. Recently, tissue protective functions of EPO have been separated from its hematopoietic actions leading to the development of EPO derivatives and mimetics. Neuroscientists are focusing on recombinant human EPO (rhEPO) and its non-erythropoietic derivatives, investigating their anti-apoptotic potential and anti-inflammatory function as well as their role in restoring vascular integrity. Carbamylated erythropoietin (CEPO) and asialo erythropoietin (AsialoEPO) are structural derivatives of EPO that have no effect on erythrocyte mass whereas they retain its neuroprotective effects. In this review article, we provide a short overview of the animal studies on rhEPO and its derivatives in experimental models of SCI.
Both the efficacy and the safety profile of EPO-structural and functional variants are still to be demonstrated in patients. Further clinical studies should reveal whether derivatives and variants of erythropoietin provide any benefits over the use of rhEPO in the treatment of spinal cord injury observed in the experimental studies.
Export Options
About this article
Cite this article as:
Mofidi A., Bader A. and Pavlica S., The Use of Erythropoietin and its Derivatives to Treat Spinal Cord Injury, Mini-Reviews in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/138955711796355267
DOI https://dx.doi.org/10.2174/138955711796355267 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs
Recent Patents on CNS Drug Discovery (Discontinued) A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Regulation of Ingestive Behavior, the Upper Gastrointestinal Motility and Gastric Acid Secretion by Ghrelin in Mammals
Current Nutrition & Food Science Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Current Trend and Pro-survival Approaches for Augmenting Stem Cell Viability
Current Pharmaceutical Biotechnology DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Transcranial Direct Current Stimulation - An Adjuvant Tool for the Treatment of Neuropsychiatric Diseases?
Current Psychiatry Reviews SOD1 Aggregation and ALS: Role of Metallation States and Disulfide Status
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator)
CNS & Neurological Disorders - Drug Targets Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury
Current Drug Targets - CNS & Neurological Disorders Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry